Investor Presentation

Here's a concise, retail-friendly summary: **Business Performance:** GSK Pharma reported solid Q3 results: Revenue at ₹1023 Cr (+8.1%), PAT at ₹277 Cr (+21.3%), and EBITDA at ₹368 Cr (+26.7%). General Medicines, Specialty, and Pediatric Vaccines were key drivers, leading to 10.5% in-market growth. **Growth Drivers or Strategy:** Strategic focus areas include strengthening key brands in General Medicines & Established Vaccines, scaling Oncology, and establishing adult immunization (Shingrix). **Recent Developments:** Shingrix saw significant traction with 50,000 Q3 prescriptions (+80% YoY). Oncology showed momentum after RUBY-1 approval.

Digital efforts boosted reach to over 360,000 healthcare professionals. **Key Financial Metrics:** * Q3 Revenue: ₹1023 Cr (+8.1% YoY) * Q3 PAT: ₹277 Cr (+21.3% YoY) * Q3 EPS: ₹16.36 (+9%) * Cash: ₹2426 Cr **Management Commentary / Outlook:** Management highlighted improving profitability via better gross margins and operating leverage.

Field productivity increased 11%, boosting cost efficiency.

Portfolio transformation and innovation in Oncology and Established Vaccines remain priorities.